-
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks A Significant Shift In Chronic Obstructive Pulmonary Disease Treatment Landscape Delveinsight
12 Nov 2024 23:46 GMT
… Onbrez, Serevent, and Brovana are included, while the LAMA class features drugs … drugs @ Drugs for COPD Treatment
Recently, Sanofi/Regeneron Pharmaceuticals … BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, …
-
‘Our next target is anticancer drug,’ Handok chairman says
16 Feb 2023 07:41 GMT
… introduce Novartis’ new products (Onbrez, Xoterna, Enerzair, and … drugs, Pemigatinib and Tafasitamab.
“Handok’s weakness as a pharmaceutical … development (of new anticancer drugs). "
Handok has … ) treatment from Alexion Pharmaceutical, and growing it to …
-
Handok to market Novartis' respiratory drugs in Korea
21 Dec 2022 04:59 GMT
Handok and Novartis Korea signed a 2023 sales contract for three additional types of the latter's respiratory treatments in Korea.
Handok was in charge of domestic sales of Onbrez in 2013, and with this contract, it will be in charge of distribution, …
-
Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio
06 Jan 2020 22:33 GMT
… chronic obstructive pulmonary disease (COPD) drugs market 2019-2023 (Graphic: Business … . UTIBRON NEOHALER, SEEBRI NEOHALER, and ONBREZ BREEZHALER are some of the … of the company.
Teva Pharmaceutical
Teva Pharmaceutical operates the business across segments …